Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD) is the leading cause of dementia. Currently, there are no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been widely used to repurpose licensed drugs and discover novel therapeutic targets. Thus, we aimed to identify novel therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Wei-Ming, Gu, Xiao-Jing, Dou, Meng, Duan, Qing-Qing, Jiang, Zheng, Yin, Kang-Fu, Cai, Wei-Chen, Cao, Bei, Wang, Yi, Chen, Yong-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cognition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579488/
https://www.ncbi.nlm.nih.gov/pubmed/37349091
http://dx.doi.org/10.1136/jnnp-2023-331142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579488/
https://www.ncbi.nlm.nih.gov/pubmed/37349091
http://dx.doi.org/10.1136/jnnp-2023-331142

Ejemplares similares